Search papers, labs, and topics across Lattice.
Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China, Research Institute of Huazhong University of Science and Technology in Shenzhen, Shenzhen, China
1
0
0
19
Dual-target CD19/CD22 CAR-T-cell therapy, especially when combined with ASCT, demonstrates sustained clinical benefit and may overcome the negative prognostic impact of TP53 alterations in relapsed/refractory aggressive B-NHL.
